Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Burak Bilgin

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 11, 2024
A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative reviewSafa Can Efil, Burak Bilgin, Furkan Ceylan, et al.
Journal of Clinical Medicine|January 11, 2025
Large Unstained Cells (LUC): A Novel Predictor of CDK4/6 Inhibitor Outcomes in HR+ HER2-Negative Metastatic Breast CancerFurkan Ceylan, Mirmehdi Mehdiyev, Didem Şener Dede, et al.
Expert Review of Anticancer Therapy|April 9, 2025
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancerFurkan Ceylan, Safa Can Efil, Didem Şener Dede, et al.
Turkish Journal of Medical Sciences|July 21, 2025
Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancerFurkan Ceylan, Didem Şener Dede, Safa Can Efil, et al.
Scientific Reports|May 9, 2024
Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatmentMurat Bardakci, Hilal Karakas, Dogan Bayram, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 15, 2020
Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)Mutlu Hizal, Mehmet An Sendur, Hatime Arzu Yasar, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 27, 2019
The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancerHatime Arzu Yasar, Kadriye Bir Yucel, Cagatay Arslan, et al.
Journal of Clinical Medicine|February 27, 2026
Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter StudyMehmet Cihan İcli, Deniz Can Guven, Arif Akyildiz, et al.
The Oncologist|March 16, 2026
Comparison of Six Cycles with Four Cycles of Chemotherapy and Atezolizumab in the First-Line Treatment of ES-SCLC; A Retrospective Multicenter AnalysisHalil Göksel Güzel, Derya Kıvrak Salim, Saadettin Kılıçkap, et al.
Cancers|January 25, 2025
Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning ApproachHakan Şat Bozcuk, Leyla Sert, Muhammet Ali Kaplan, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 11, 2024
A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative reviewSafa Can Efil, Burak Bilgin, Furkan Ceylan, et al.
Journal of Clinical Medicine|January 11, 2025
Large Unstained Cells (LUC): A Novel Predictor of CDK4/6 Inhibitor Outcomes in HR+ HER2-Negative Metastatic Breast CancerFurkan Ceylan, Mirmehdi Mehdiyev, Didem Şener Dede, et al.
Expert Review of Anticancer Therapy|April 9, 2025
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancerFurkan Ceylan, Safa Can Efil, Didem Şener Dede, et al.
Turkish Journal of Medical Sciences|July 21, 2025
Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancerFurkan Ceylan, Didem Şener Dede, Safa Can Efil, et al.
Scientific Reports|May 9, 2024
Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatmentMurat Bardakci, Hilal Karakas, Dogan Bayram, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 15, 2020
Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)Mutlu Hizal, Mehmet An Sendur, Hatime Arzu Yasar, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 27, 2019
The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancerHatime Arzu Yasar, Kadriye Bir Yucel, Cagatay Arslan, et al.
Journal of Clinical Medicine|February 27, 2026
Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter StudyMehmet Cihan İcli, Deniz Can Guven, Arif Akyildiz, et al.
The Oncologist|March 16, 2026
Comparison of Six Cycles with Four Cycles of Chemotherapy and Atezolizumab in the First-Line Treatment of ES-SCLC; A Retrospective Multicenter AnalysisHalil Göksel Güzel, Derya Kıvrak Salim, Saadettin Kılıçkap, et al.
Cancers|January 25, 2025
Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning ApproachHakan Şat Bozcuk, Leyla Sert, Muhammet Ali Kaplan, et al.
Pageof 10